- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Dr. Reddy's Laboratories Limited — Board Meeting, 24-10-2025: Outcome of Board Meeting
24-10-2025 | 04:44 pm
24-10-2025 | 04:44 pm
Dr. Reddy's Board approved Q2 & H1 FY26 consolidated results. Q2 revenues hit ₹8,805.1 Cr (+9.8% YoY), with profit at ₹1,437.2 Cr (+14% YoY). Strategic moves include acquiring STUGERON® portfolio for ₹446.4 Cr and launching new drugs in India and the US. Growth was driven by branded markets and NRT sales.
No comments yet. Be the first to comment!